Science
Mechanism of Action
Acetyl Farnesylcysteine acts as a specific S-farnesylcysteine methyl transferase inhibitor, with a Km of 20 μM, which blocks the C-terminal methylation of proteins within cells. This inhibitory action modulates G protein and G protein-coupled receptor signaling, thereby diminishing inflammatory cascades. Mechanistically, AFC has been shown to inhibit neutrophil chemotaxis, reduce acute inflammation (including edema and neutrophil infiltration in vivo), and dose-dependently suppress the ATP-, ATPγS-, and TNFα-induced production of key chemokines such as CXCL1, CXCL8, and CCL2 by human dermal microvascular endothelial cells in vitro.
Research
Clinical Evidence
Low confidenceN/A
Transparency
Dusting Analysis
The Formula
Formulation
Stability
This ingredient exhibits sensitivity to temperature and oxidation, necessitating storage at -20°C under an inert gas. For reconstituted solutions, aliquoting and freezing at -20°C is recommended, with DMSO stock solutions maintaining stability for up to one month at -20°C.
Safety
Safety Profile
Acetyl Farnesylcysteine is registered with the FDA's Global Substance Registration System (UNII: KK6984C8O3) and is listed by the Personal Care Products Council (INCI), though its safety profile has not been formally reviewed by the Cosmetic Ingredient Review (CIR).
Your Skin
Skin Compatibility
Our Assessment
Verdict
Acetyl Farnesylcysteine demonstrates significant anti-inflammatory potential in vitro and in mouse models, positioning it as a promising, though currently under-researched for human clinicals, ingredient for soothing and conditioning the skin.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources